Certain populations may be at increased risk of haloperidol toxicity. Elderly patients, especially those with dementia-related psychosis, are more susceptible to adverse effects, including an increased risk of mortality. Individuals with preexisting cardiovascular conditions may also be at heightened risk due to the potential for QT interval prolongation. Additionally, genetic polymorphisms affecting the cytochrome P450 enzymes can alter drug metabolism, potentially leading to increased toxicity.
